Novel autoantigens in type 1 diabetes

American Journal of Translational Research

Volumn 5, Issue 4, 2013, Pages 379-392

  Han, Shuhong ^a   Donelan, William ^b   Wang, Hai ^b   Reeves, Westley ^a   Yang, Li Jun ^b,c  

^a Department of Medicine ^*  (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^c TIANJIN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Autoantibodies; Autoantigen; CHGA; IAPP; Immune tolerance; Immunotherapy; Pdx1; Type 1 diabetes; ZnT8

Indexed keywords

AMYLIN; AUTOANTIGEN; CHAPERONIN 60 PEPTIDE VACCINE; CHROMOGRANIN A; DIAPEP 277; GLUTAMATE DECARBOXYLASE 65; PEPTIDE VACCINE; TRANSCRIPTION FACTOR PDX 1; UNCLASSIFIED DRUG; ZINC TRANSPORTER;

CD4+ T LYMPHOCYTE; CELL CLONE; CLINICAL TRIAL (TOPIC); HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN FUNCTION; RADIOIMMUNOPRECIPITATION; REVIEW; T LYMPHOCYTE;

EID: 84878287221     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Van Belle TL, Coppieters KT and von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91: 79-118.
2. Zhang L, Gianani R, Nakayama M, Liu E, Kobayashi M, Baschal E, Yu L, Babu S, Dawson A, Johnson K, Jahromi M, Aly T, Fain P, Barker J, Rewers M and Eisenbarth GS. Type 1 diabetes: chronic progressive autoimmune disease. Novartis. Found Symp 2008; 292: 85-94.
3. Zhang L and Eisenbarth GS. Prediction and prevention of Type 1 diabetes mellitus. J Diabetes 2011; 3: 48-57.
4. Coppieters KT, Dotta F, Amirian N, Campbell PD, Kay TW, Atkinson MA, Roep BO and von Herrath MG. Demonstration of islet-autoreactive CD8 T cells in insulitic lesions from recent onset and long-term type 1 diabetes patients. J Exp Med 2012 Jan 16; 209: 51-60.
5. Reijonen H, Novak EJ, Kochik S, Heninger A, Liu AW, Kwok WW and Nepom GT. Detection of GAD65-specific T-cells by major histocompatibility complex class II tetramers in type 1 diabetic patients and at-risk subjects. Diabetes 2002; 51: 1375-1382.
6. Lazzarotto F, Basso D, Plebani M, Moscon A, Zanchetta R and Betterle C. Celiac disease and type 1 diabetes. Diabetes Care 2003; 26: 248-249.
7. Winter WE, Harris N and Schatz D. Type 1 diabetes islet autoantibody markers. Diabetes Technol Ther 2002; 4: 817-839.
8. Bottazzo GF, Florin-Christensen A and Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet 1974 Nov 30; 2: 1279-1283.
9. Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK and Paquette TL. Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science 1983 Dec 23; 222: 1337-1339.
10. Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H and De Camilli P. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990 Sep 13; 347: 151-156.
11. Bonifacio E, Lampasona V and Bingley PJ. IA-2 (islet cell antigen 512) is the primary target of humoral autoimmunity against type 1 diabetes-associated tyrosine phosphatase autoantigens. J Immunol 1998 Sep 1; 161: 2648-2654.
12. Birk OS, Elias D, Weiss AS, Rosen A, van der Zee R, Walker MD and Cohen IR. NOD mouse diabetes: the ubiquitous mouse hsp60 is a beta-cell target antigen of autoimmune T cells. J Autoimmun 1996; 9: 159-166.
13. Yang J, Danke NA, Berger D, Reichstetter S, Reijonen H, Greenbaum C, Pihoker C, James EA and Kwok WW. Islet-specific glucose-6-phosphatase catalytic subunit-related protein-reactive CD4+ T cells in human subjects. J Immunol 2006 Mar 1; 176: 2781-2789.
14. Arden SD, Roep BO, Neophytou PI, Usac EF, Duinkerken G, de Vries RR and Hutton JC. Imogen 38: a novel 38-kD islet mitochondrial autoantigen recognized by T cells from a newly diagnosed type 1 diabetic patient. J Clin Invest 1996 Jan 15; 97: 551-561.
15. Wenzlau JM, Juhl K, Yu L, Moua O, Sarkar SA, Gottlieb P, Rewers M, Eisenbarth GS, Jensen J, Davidson HW and Hutton JC. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007 Oct 23; 104: 17040-17045.
16. Li SW, Koya V, Li Y, Donelan W, Lin P, Reeves WH and Yang LJ. Pancreatic duodenal homeobox 1 protein is a novel beta-cell-specific autoantigen for type I diabetes. Lab Invest 2010; 90: 31-39.
17. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Piganelli JD, Barbour G, Bradley B, Crawford F, Marrack P, Mahata SK, Kappler J and Haskins K. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11: 225-231.
18. Delong T, Baker RL, Reisdorph N, Reisdorph R, Powell RL, Armstrong M, Barbour G, Bradley B and Haskins K. Islet amyloid polypeptide is a target antigen for diabetogenic CD4+ T cells. Diabetes 2011; 60: 2325-2330.
19. Jasinski JM and Eisenbarth GS. Insulin as a primary autoantigen for type 1A diabetes. Clin Dev Immunol 2005; 12: 181-186.
20. Mallone R, Brezar V and Boitard C. T cell recognition of autoantigens in human type 1 diabetes: clinical perspectives. Clin Dev Immunol 2011; 2011: 513210.
21. Roep BO and Peakman M. Antigen targets of type 1 diabetes autoimmunity. Cold Spring Harb Perspect Med 2012; 2: a007781
22. Haskins K and Cooke A. CD4 T cells and their antigens in the pathogenesis of autoimmune diabetes. Curr Opin Immunol 2011; 23: 739-745.
23. Stadinski B, Kappler J and Eisenbarth GS. Molecular targeting of islet autoantigens. Immunity 2010 Apr 23; 32: 446-456.
24. Yoon JW and Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005; 12: 580-591.
25. Zekzer D, Wong FS, Ayalon O, Millet I, Altieri M, Shintani S, Solimena M and Sherwin RS. GADreactive CD4+ Th1 cells induce diabetes in NOD/SCID mice. J Clin Invest 1998 Jan 1; 101: 68-73.
26. Yoon JW, Yoon CS, Lim HW, Huang QQ, Kang Y, Pyun KH, Hirasawa K, Sherwin RS and Jun HS. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science 1999 May 14; 284: 1183-1187.
27. Nakayama M. Insulin as a key autoantigen in the development of type 1 diabetes. Diabetes Metab Res Rev 2011; 27: 773-777.
28. Honeyman MC, Harrison LC, Drummond B, Colman PG and Tait BD. Analysis of families at risk for insulin-dependent diabetes mellitus reveals that HLA antigens influence progression to clinical disease. Mol Med 1995; 1: 576-582.
29. Panina-Bordignon P, Lang R, van Endert PM, Benazzi E, Felix AM, Pastore RM, Spinas GA and Sinigaglia F. Cytotoxic T cells specific for glutamic acid decarboxylase in autoimmune diabetes. J Exp Med 1995 May 1; 181: 1923-1927.
30. Oling V, Reijonen H, Simell O, Knip M and Ilonen J. Autoantigen-specific memory CD4+ T cells are prevalent early in progression to Type 1 diabetes. Cell Immunol 2012; 273: 133-139.
31. Raz I, Elias D, Avron A, Tamir M, Metzger M and Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001 Nov 24; 358: 1749-1753.
32. Wong FS. Insulin--a primary autoantigen in type 1 diabetes? Trends Mol Med 2005; 11: 445-448.
33. Winter WE and Schatz DA. Autoimmune markers in diabetes. Clin Chem 2011; 57: 168-175.
34. Ludvigsson J. In light of recent clinical trial results, what lies next for Type 1 diabetes vaccine research? Expert Rev Vaccines 2012; 11: 263-265.
35. Phillips B, Trucco M and Giannoukakis N. Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same? Clin Dev Immunol 2011; 2011: 432016.
36. Ludvigsson J, Krisky D, Casas R, Battelino T, Castano L, Greening J, Kordonouri O, Otonkoski T, Pozzilli P, Robert JJ, Veeze HJ and Palmer J. GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus. N Engl J Med 2012 Feb 2; 366: 433-442.
37. Nicholas D, Odumosu O and Langridge WH. Autoantigen based vaccines for type 1 diabetes. Discov Med 2011; 11: 293-301.
38. Boettler T and von Herrath M. Immunotherapy of type 1 diabetes--how to rationally prioritize combination therapies in T1D. Int Immunopharmacol 2010; 10: 1491-1495.
39. Todd JA, Knip M and Mathieu C. Strategies for the prevention of autoimmune type 1 diabetes. Diabet Med 2011; 28: 1141-1143.
40. Chimienti F, Favier A and Seve M. ZnT-8, a pancreatic beta-cell-specific zinc transporter. Biometals 2005; 18: 313-317.
41. Kawasaki E. ZnT8 and type 1 diabetes [Review]. Endocr J 2012 Jul 31; 59: 531-7.
42. Howson JM, Krause S, Stevens H, Smyth DJ, Wenzlau JM, Bonifacio E, Hutton J, Ziegler AG, Todd JA and Achenbach P. Genetic association of zinc transporter 8 (ZnT8) autoantibodies in type 1 diabetes cases. Diabetologia 2012; 55: 1978-1984.
43. Vaziri-Sani F, Oak S, Radtke J, Lernmark K, Lynch K, Agardh CD, Cilio CM, Lethagen AL, Ortqvist E, Landin-Olsson M, Torn C and Hampe CS. ZnT8 autoantibody titers in type 1 diabetes patients decline rapidly after clinical onset. Autoimmunity 2010; 43: 598-606.
44. Wenzlau JM, Walter M, Gardner TJ, Frisch LM, Yu L, Eisenbarth GS, Ziegler AG, Davidson HW and Hutton JC. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010; 95: 4712-4719.
45. Andersen ML, Vaziri-Sani F, Delli A, Porksen S, Jacobssen E, Thomsen J, Svensson J, Steen Petersen J, Hansen L, Lernmark A, Mortensen HB and Nielsen LB. Association between autoantibodies to the Arginine variant of the Zinc transporter 8 (ZnT8) and stimulated C-peptide levels in Danish children and adolescents with newly diagnosed type 1 diabetes. Pediatr Diabetes 2012 Sep; 13: 454-62.
46. Nielsen LB, Vaziri-Sani F, Porksen S, Andersen ML, Svensson J, Bergholdt R, Pociot F, Hougaard P, de Beaufort C, Castano L, Mortensen HB, Lernmark A and Hansen L. Relationship between ZnT8Ab, the SLC30A8 gene and disease progression in children with newly diagnosed type 1 diabetes. Autoimmunity 2011; 44: 616-623.
47. Tabara Y, Osawa H, Kawamoto R, Onuma H, Shimizu I, Makino H, Kohara K and Miki T. Genotype risk score of common susceptible variants for prediction of type 2 diabetes mellitus in Japanese: the Shimanami Health Promoting Program (J-SHIPP study). Development of type 2 diabetes mellitus and genotype risk score. Metabolism 2011; 60: 1634-1640.
48. Dang M, Rockell J, Wagner R, Wenzlau JM, Yu L, Hutton JC, Gottlieb PA and Davidson HW. Human type 1 diabetes is associated with T cell autoimmunity to zinc transporter 8. J Immunol 2011 May 15; 186: 6056-6063.
49. Enee E, Kratzer R, Arnoux JB, Barilleau E, Hamel Y, Marchi C, Beltrand J, Michaud B, Chatenoud L, Robert JJ and van Endert P. ZnT8 Is a Major CD8+ T Cell-Recognized Autoantigen in Pediatric Type 1 Diabetes. Diabetes 2012; 61: 1779-1784.
50. Scotto M, Afonso G, Larger E, Raverdy C, Lemonnier FA, Carel JC, Dubois-Laforgue D, Baz B, Levy D, Gautier JF, Launay O, Bruno G, Boitard C, Sechi LA, Hutton JC, Davidson HW and Mallone R. Zinc transporter (ZnT)8(186-194) is an immunodominant CD8+ T cell epitope in HLAA2+ type 1 diabetic patients. Diabetologia 2012; 55: 2026-2031.
51. Wu X, Xu X, Gu R, Wang Z, Chen H, Xu K, Zhang M, Hutton J and Yang T. Prediction of HLA class I-restricted T-cell epitopes of islet autoantigen combined with binding and dissociation assays. Autoimmunity 2012; 45: 176-185.
52. Hui H and Perfetti R. Pancreas duodenum homeobox-1 regulates pancreas development during embryogenesis and islet cell function in adulthood. Eur J Endocrinol 2002; 146: 129-141.
53. Stoffel M, Stein R, Wright CV, Espinosa R 3rd, Le Beau MM and Bell GI. Localization of human homeodomain transcription factor insulin promoter factor 1 (IPF1) to chromosome band 13q12.1. Genomics 1995 Jul 1; 28: 125-126.
54. Al-Quobaili F and Montenarh M. Pancreatic duodenal homeobox factor-1 and diabetes mellitus type 2 (review). Int J Mol Med 2008; 21: 399-404.
55. Macfarlane WM, McKinnon CM, Felton-Edkins ZA, Cragg H, James RF and Docherty K. Glucose stimulates translocation of the homeodomain transcription factor PDX1 from the cytoplasm to the nucleus in pancreatic beta-cells. J Biol Chem 1999 Jan 8; 274: 1011-1016.
56. Marshak S, Totary H, Cerasi E and Melloul D. Purification of the beta-cell glucose-sensitive factor that transactivates the insulin gene differentially in normal and transformed islet cells. Proc Natl Acad Sci U S A 1996 Dec 24; 93: 15057-15062.
57. Stoffers DA, Zinkin NT, Stanojevic V, Clarke W L and Habener JF. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15: 106-110.
58. Stoffers DA, Ferrer J, Clarke WL and Habener JF. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997; 17: 138-139.
59. Jonsson J, Carlsson L, Edlund T and Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature 1994 Oct 13; 371: 606-609.
60. Offield MF, Jetton TL, Labosky PA, Ray M, Stein RW, Magnuson MA, Hogan BL and Wright CV. PDX-1 is required for pancreatic outgrowth and differentiation of the rostral duodenum. Development 1996; 122: 983-995.
61. Koya V, Lu S, Sun YP, Purich DL, Atkinson MA, Li SW and Yang LJ. Reversal of streptozotocininduced diabetes in mice by cellular transduction with recombinant pancreatic transcription factor pancreatic duodenal homeobox-1: a novel protein transduction domain-based therapy. Diabetes 2008; 57: 757-769.
62. Shternhall-Ron K, Quintana FJ, Perl S, Meivar-Levy I, Barshack I, Cohen IR and Ferber S. Ectopic PDX-1 expression in liver ameliorates type 1 diabetes. J Autoimmun 2007; 28: 134-142.
63. Thomas JO, Wilson CM and Hardin JA. The major core histone antigenic determinants in systemic lupus erythematosus are in the trypsinsensitive regions. FEBS Lett 1984 Apr 9; 169: 90-96.
64. James JA, Scofield RH and Harley JB. Basic amino acids predominate in the sequential autoantigenic determinants of the small nuclear 70K ribonucleoprotein. Scand J Immunol 1994; 39: 557-566.
65. Baxter AG, Healey D and Cooke A. Mycobacteria precipitate autoimmune rheumatic disease in NOD mice via an adjuvant-like activity. Scand J Immunol 1994; 39: 602-606.
66. Brendel V, Dohlman J, Blaisdell BE and Karlin S. Very long charge runs in systemic lupus erythematosus-associated autoantigens. Proc Natl Acad Sci U S A 1991 Feb 15; 88: 1536-1540.
67. Pollard KM and Cohen MG. Predicting antigenic determinants of autoantigens. Autoimmunity 1990; 5: 265-275.
68. Fenalti G, Hampe CS, Arafat Y, Law RH, Banga JP, Mackay IR, Whisstock JC, Buckle AM and Rowley MJ. COOH-terminal clustering of autoantibody and T-cell determinants on the structure of GAD65 provide insights into the molecular basis of autoreactivity. Diabetes 2008; 57: 1293-1301.
69. Liu J, Purdy LE, Rabinovitch S, Jevnikar AM and Elliott JF. Major DQ8-restricted T-cell epitopes for human GAD65 mapped using human CD4, DQA1*0301, DQB1*0302 transgenic IA(null) NOD mice. Diabetes 1999; 48: 469-477.
70. Dromey JA, Weenink SM, Peters GH, Endl J, Tighe PJ, Todd I and Christie MR. Mapping of epitopes for autoantibodies to the type 1 diabetes autoantigen IA-2 by peptide phage display and molecular modeling: overlap of antibody and T cell determinants. J Immunol 2004 Apr 1; 172: 4084-4090.
71. Helle KB, Corti A, Metz-Boutigue MH and Tota B. The endocrine role for chromogranin A: a prohormone for peptides with regulatory properties. Cell Mol Life Sci 2007; 64: 2863-2886.
72. Nikoopour E, Sandrock C, Huszarik K, Krougly O, Lee-Chan E, Masteller EL, Bluestone JA and Singh B. Cutting edge: vasostatin-1-derived peptide ChgA29-42 is an antigenic epitope of diabetogenic BDC2.5 T cells in nonobese diabetic mice. J Immunol 2011 Apr 1; 186: 3831-3835.
73. Loh YP, Cheng Y, Mahata SK, Corti A and Tota B. Chromogranin A and Derived Peptides in Health and Disease. J Mol Neurosci 2012 Mar 3; 48: 347-56.
74. Konecki DS, Benedum UM, Gerdes HH and Huttner WB. The primary structure of human chromogranin A and pancreastatin. J Biol Chem 1987 Dec 15; 262: 17026-17030.
75. Singh S and Law C. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol 2012; 6: 313-334.
76. Doyle HA and Mamula MJ. Autoantigenesis: the evolution of protein modifications in autoimmune disease. Curr Opin Immunol 2012; 24: 112-118.
77. Mannering SI, Harrison LC, Williamson NA, Morris JS, Thearle DJ, Jensen KP, Kay TW, Rossjohn J, Falk BA, Nepom GT and Purcell AW. The insulin A-chain epitope recognized by hu man T cells is posttranslationally modified. J Exp Med 2005 Nov 7; 202: 1191-1197.
78. Stridsberg M and Wilander E. Islet amyloid polypeptide (IAPP). A short review. Acta Oncol 1991; 30: 451-456.
79. Westermark P, Andersson A and Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 2011; 91: 795-826.
80. Clark A, Yon SM, de Koning EJ and Holman RR. Autoantibodies to islet amyloid polypeptide in diabetes. Diabet Med 1991; 8: 668-673.
81. Westermark P, Engstrom U, Johnson KH, Westermark GT and Betsholtz C. Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A 1990; 87: 5036-5040.
82. Tomita T. Islet amyloid polypeptide in pancreatic islets from type 1 diabetic subjects. Islets 2011; 3: 166-174.
83. Di Lorenzo TP, Peakman M and Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148: 1-16.
84. Panagiotopoulos C, Qin H, Tan R and Verchere CB. Identification of a beta-cell-specific HLA class I restricted epitope in type 1 diabetes. Diabetes 2003; 52: 2647-2651.